Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02092909
Title Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401)
Acronym 8400-401
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Idera Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Cancer Centers of Excellence Fayetteville Arkansas 72758 United States Details
UCLA Los Angeles California 90404 United States Details
Mayo Clinic Jacksonville Jacksonville Florida 32224 United States Details
Emory Winship Cancer Institute Atlanta Georgia 30322 United States Details
Horizon BioAdvance Lafayette Indiana 47905 United States Details
Mayo Clinic Rochester Minnesota 55902 United States Details
Hackensack University Hackensack New Jersey 07601 United States Details
Memorial Sloan-Kettering Cancer Center New York New York 10065 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field